Rockwell Medical, Inc. RMTI

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
47/100
Developing

About Rockwell Medical, Inc.

Rockwell Medical, Inc., together with its subsidiaries, develops, manufactures, commercializes, and distributes various hemodialysis products for dialysis providers worldwide. The company offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, centrisol and renasol hemodialysis concentrates, and dry acid concentrate mixer, as well as … Full RMTI analysis →

Competitive advantage assessment

Key strengths

  • Strong Liquidity Buffer Liquidity position is strong (score 0.76), providing operational cushion.
  • Operating Leverage in Effect Operating leverage is evident (score 0.68), with margins expanding over time.

Key risks

  • Scale Without Profitability Despite scale, profitability lags peers (score 0.33), suggesting limited competitive advantage.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
32

Where RMTI ranks in Drug Manufacturers - Specialty & Generic

Rockwell Medical, Inc. ranks #36 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 40%. The widest moat in the group is Zoetis Inc. (ZTS) at 85/100.

Moat scores for companies ranked near RMTI in Drug Manufacturers - Specialty & Generic
# Company Moat score Rating
32 Cumberland Pharmaceuticals Inc. CPIX 54/100 Moderate
33 Dynavax Technologies Corporatio DVAX 52/100 Moderate
34 HUTCHMED (China) Limited HCM 51/100 Moderate
35 Esperion Therapeutics, Inc. ESPR 50/100 Developing
36 Rockwell Medical, Inc. RMTI 47/100 Developing
37 Evotec SE EVO 47/100 Developing
38 Eton Pharmaceuticals, Inc. ETON 46/100 Developing
39 Cronos Group Inc. Common Share CRON 46/100 Developing
40 Tilray Brands, Inc. TLRY 45/100 Developing

See every Pharma / Mature Biotech company ranked by moat score →

How RMTI scores on the Corporate Default defenses

Pricing Power

Score 32 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 70 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 51 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 25 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 65 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 47 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding RMTI's moat

What is Rockwell Medical, Inc.'s moat score?

Rockwell Medical, Inc. (RMTI) scores 47 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #36 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 40%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Cost Advantage (70/100) and its weakest is Capital Efficiency (25/100).

How does Rockwell Medical, Inc. compare with other Drug Manufacturers - Specialty & Generic companies?

Rockwell Medical, Inc. ranks #36 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are Esperion Therapeutics, Inc. (ESPR) at 50 just above it and Evotec SE (EVO) at 47 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.

Why is Rockwell Medical, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Rockwell Medical, Inc.?

The Corporate Default template measures 6 defenses, and RMTI scores: Pricing Power (32), Cost Advantage (70), Customer Stickiness (51), Capital Efficiency (25), Resilience (65), Scale & Market Position (47). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000